Enterome logo

Enterome

Delivering the promise of immunotherapy

49 employees · est. 2011 · Paris, France

VS
Oncolix logo

Oncolix

Pioneering new horizons in ovarian cancer treatment with a focus on autophagy through our innovative prolactin receptor antagonist.

0-1 employees · est. 2007

Oncolix is the older company (2011 vs 2007); Enterome is the larger of the two.

Side-by-Side Comparison

Enterome Oncolix
Founded
2011 2007 older
Headquarters
Paris, France Not tracked yet
Employees
49 larger 0-1
Industry
Biopharma, Biotechnology, Health Care Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series Unknown Series Unknown
Total Funding
$175.80M $8.46M
Funding Rounds
9 4
Services
Development of off-the-shelf cancer immunotherapy treatments Not tracked yet
Target Customers
Patients with B cell malignancies, Glioblastoma, adrenal tumors, and colorectal cancer Not tracked yet
Taxonomy
Immunotherapy, Biopharmaceuticals, Drug Discovery, OncoMimics, Cancer Treatment, Immunomodulatory Drugs, Phase 2 Clinical Trials, Tumor Associated Antigens, CD8 T Cell Response, Glioblastoma, Adrenal Malignancies, Colorectal Cancer, Clinical-stage Biotech, Immunotherapies, Metagenomics Clinical-stage, Cancer Treatment, Phase I Clinical Trial, Ovarian Cancer, Prolanta, Prolactin Receptor Antagonist, Autophagy, Oncology, Innovation
Website
enterome.com oncolixbio.com
Enterome logo

About Enterome

Enterome is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in France. It focuses on delivering the promise of immunotherapy through the development of breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. The company's unique approach to d...

Oncolix logo

About Oncolix

Oncolix, a clinical-stage biotechnology company founded in 2007, is currently focused on pioneering new horizons in ovarian cancer treatment. The company's slogan emphasizes its commitment to innovation in this field, particularly through the development of an innovative prolactin receptor antagonis...

We will tell you when either one moves

BounceWatch watches Enterome and Oncolix for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Enterome and Oncolix — by email.

Frequently Asked Questions

Enterome — Delivering the promise of immunotherapy. Oncolix — Pioneering new horizons in ovarian cancer treatment with a focus on autophagy through our innovative prolactin receptor antagonist.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Enterome has raised $175.80M while Oncolix has raised $8.46M.
Enterome and Oncolix operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Enterome with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Enterome on 7 Jun 2025, and Oncolix on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy